Journal
FEBS JOURNAL
Volume 289, Issue 12, Pages 3317-3334Publisher
WILEY
DOI: 10.1111/febs.15814
Keywords
adjuvants; envelope glycoproteins; HIV‐ 1; immune response; vaccines
Categories
Funding
- Center Grant of the Academic Investment Research Program (AIRP) of the Medical School at the University of Minnesota
Ask authors/readers for more resources
Protection from HIV acquisition may require an effective vaccine that elicits antibodies against HIV-1 envelope glycoproteins, with adjuvants playing a crucial role in enhancing immune responses. Various adjuvants have been used in combination with HIV-1 envelope glycoproteins in recent years, showing potential to improve antibody responses and guide specific antibody formation.
Protection from human immunodeficiency virus (HIV) acquisition will likely require an effective vaccine that elicits antibodies against the HIV-1 envelope glycoproteins (Envs), which are the sole target of neutralizing antibodies and a main focus of vaccine development. Adjuvants have been widely used to augment the magnitude and longevity of the adaptive immune responses to immunizations with HIV-1 Envs and to guide the development of specific immune responses. Here, we review the adjuvants that have been used in combination with HIV-1 Envs in several preclinical and human clinical trials in recent years. We summarize the interactions between the HIV-1 Envs and adjuvants, and highlight the routes of vaccine administration for various formulations. We then discuss the use of combinations of different adjuvants, the potential effect of adjuvants on the elicitation of antibodies enriched in somatic hypermutation and containing long complementarity-determining region 3 of the antibody heavy chain, and the elicitation of non-neutralizing antibodies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available